Related Experiment Videos
Effects of K+-canrenoate on the development of DOCA-salt hypertension
1Department of Biochemistry, Faculty of Medicine, University of Granada, Spain.
Abstract:
The effects of K+-canrenoate, a digoxin antagonist, on the role of digoxin-like factor in the development of DOCA-salt hypertension has been examined. DOCA-salt rats treated with 66 mg kg-1 day-1 of K+-canrenoate (s.c.) presented a lower increase in blood pressure (P less than 0.01), less cardiac hypertrophy (P less than 0.05) and hypokalaemia (P less than 0.05) than non-treated DOCA-salt rats. K+-canrenoate treatment did not lead to significant changes in urinary volume, Na+ and K+ urinary excretion or suppression of plasma renin activity in DOCA-salt rats. None of the parameters were significantly different between uninephrectomized-salt rats treated or non-treated with K+-canrenoate. These data suggest a role for digoxin-like factor in DOCA-salt hypertension. However, the non-normalization of blood pressure observed in K+-canrenoate DOCA-salt treated rats indicates that other factors contribute to the initiating mechanisms in this type of hypertension. Moreover, these data suggest that digoxin-like factor plays no role in the suppression of plasma renin activity induced by DOCA and salt treatment.
Insights
K+-canrenoate, a digoxin antagonist, reduced blood pressure and cardiac hypertrophy in DOCA-salt rats, suggesting a role for digoxin-like factors in hypertension development. However, it did not fully normalize blood pressure, indicating other contributing factors.
Area of Science:
- Cardiovascular Physiology
- Endocrinology
- Pharmacology
Background:
- Deoxycorticosterone acetate (DOCA)-salt hypertension is a model used to study high blood pressure.
- Digoxin-like factor (DLF) is implicated in cardiovascular regulation and hypertension.
- K+-canrenoate is a known antagonist of digoxin and may influence DLF activity.
Purpose of the Study:
- To investigate the role of digoxin-like factor in DOCA-salt hypertension.
- To examine the effects of K+-canrenoate, a digoxin antagonist, on DOCA-salt induced hypertension.
- To determine if K+-canrenoate influences other physiological parameters associated with hypertension.
Main Methods:
- DOCA-salt rats were treated with K+-canrenoate (66 mg/kg/day, s.c.).
- Blood pressure, cardiac hypertrophy, and hypokalemia were measured.
- Urinary volume, sodium and potassium excretion, and plasma renin activity were assessed.
- Comparisons were made between treated and non-treated DOCA-salt rats, as well as uninephrectomized-salt rats.
Main Results:
- K+-canrenoate treatment significantly reduced blood pressure increase (P < 0.01) and cardiac hypertrophy (P < 0.05) in DOCA-salt rats.
- Hypokalemia was also reduced (P < 0.05) in treated rats.
- No significant changes were observed in urinary volume, Na+ and K+ excretion, or plasma renin activity.
- No significant differences were found in uninephrectomized-salt rats with or without K+-canrenoate treatment.
Conclusions:
- Digoxin-like factor appears to play a role in the development of DOCA-salt hypertension.
- K+-canrenoate treatment partially mitigates hypertension but does not normalize blood pressure, suggesting other factors are involved.
- Digoxin-like factor does not seem to be involved in the suppression of plasma renin activity observed in DOCA-salt hypertension.